Journal of investigative medicine : the official publication of the American Federation for Clinical Research最新文献

{"title":"2026 9th International Conference on Advances in Biological Science and Technology Selected Meeting Abstracts Supplement.","authors":"","doi":"10.1177/10815589261491545","DOIUrl":"https://doi.org/10.1177/10815589261491545","url":null,"abstract":"","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":"74 2_suppl","pages":"1-14"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond body mass index: Retinal microvascular imaging opens a new perspective on cardiometabolic risk in childhood obesity.","authors":"Hande Erman, Banu Böyük, Nursal Melda Yenerel","doi":"10.1177/10815589261497359","DOIUrl":"https://doi.org/10.1177/10815589261497359","url":null,"abstract":"","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497359"},"PeriodicalIF":2.0,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations, hurdles, and ethics of database research.","authors":"Mark E Schweitzer","doi":"10.1177/10815589261493455","DOIUrl":"https://doi.org/10.1177/10815589261493455","url":null,"abstract":"","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261493455"},"PeriodicalIF":2.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Effects of Selenium Supplementation on Cognitive Function in Patients with Hyperthyroidism Caused by Graves' disease: A Randomized Prospective Study.","authors":"Jianli Huang, Li Liu, Wenfu Tao, Jiayu Luo, Jinyue Meng, Yuanyuan Lin, Guangjing Huang, Hui Wei, Xuemei Huang","doi":"10.1177/10815589261497366","DOIUrl":"https://doi.org/10.1177/10815589261497366","url":null,"abstract":"<p><strong>Background: </strong>The study investigated the effects of selenium supplementation on cognitive function in patients with Graves' hyperthyroidism.</p><p><strong>Methods: </strong>A total of 124 newly diagnosed patients with Graves' hyperthyroidism and with a baseline Montreal Cognitive Assessment (MoCA) score < 26 were recruited. Participants were randomly assigned to either the conventional treatment group (n = 62) or the combined treatment group (n = 62). Cognitive and biochemical assessments were conducted at baseline and at 4, 8, and 12 weeks post-intervention. The primary outcomes were MoCA score and blood selenium concentration. Secondary outcomes included total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH) and thyroid receptor antibodies (TRAb).</p><p><strong>Results: </strong>At the 4th, 8th and 12th weeks of follow-up, the MoCA scores, blood selenium concentrations and TSH levels in the combined treatment group were significantly higher than those in the conventional treatment group (all p < 0.05), whereas TRAb levels were significantly lower (p < 0.05). Linear mixed-effects modeling revealed statistically significant group × time interactions for MoCA scores (β = 1.914, 95% CI: 1.152-2.018, p = 0.012), blood selenium concentrations (β = 21.132, 95% CI: 18.302-30.171, p < 0.001), TRAb levels (β = -3.286, 95% CI: -5.575- -1.120, p < 0.001) and TSH levels (β = 1.136, 95% CI: 0.812-1.398, p < 0.001). Linear correlation analysis demonstrated that changes in blood selenium concentrations from baseline to at week 12 were moderately positively correlated with changes in MoCA scores (r = 0.538, p < 0.001), moderately negatively correlated with changes in FT4 levels (r = -0.437, p < 0.001), and strongly negatively correlated with changes in TRAb levels (r = - 0.722, p < 0.001). Partial correlation analysis confirmed that changes in blood selenium concentrations remained significantly negatively associated with changes in TRAb levels (r = - 0.690, p < 0.001). Furthermore, binary logistic regression analysis indicated that improvement in cognitive function among patients with Graves' hyperthyroidism was significantly associated with treatment modality (OR = 0.046, 95% CI: 0.017-0.123, p < 0.001).</p><p><strong>Conclusion: </strong>Selenium supplementation therapy confers significant cognitive benefits in patients with Graves' hyperthyroidism.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497366"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Vitamin D and cancer connection: Is it a promise for cancer Prevention?","authors":"Abdullah Baothman, Olfat Shaker, Duaa Eliwa Mohamed Eliwa, Gaber El-Saber Batiha","doi":"10.1177/10815589261497362","DOIUrl":"https://doi.org/10.1177/10815589261497362","url":null,"abstract":"<p><p>Traditionally, vitamin D has been recognized primarily for its role in regulating calcium homeostasis and supporting skeletal integrity. Current research has found growing evidences of other biological processes involving vitamin D that contribute to cancer etiology and pathogenesis. Recently, increasing scientific attention has focused on the potential protective role of vitamin D against cancer, mediated through its regulation of cellular proliferation and differentiation, modulation of immune responses, and inhibition of metastatic processes. Current scientific interest in this area is substantial due to the high prevalence of vitamin D deficiency, even in populations with sufficient sunlight exposure and supplement intake, alongside the global rise in cancer incidence. A key research challenge is to elucidate the potential association between vitamin D deficiency and increased cancer risk through critical evaluation of existing literature, which often presents inconsistent and conflicting findings.This narrative literature review aims to synthesize the existing evidence on the relationship between vitamin D and cancer, with particular emphasis on VDR-mediated molecular mechanisms involved in carcinogenesis, including antiproliferative and anti-metastatic actions, as well as modulation of immune system responses. In contrast to the bulk of previous studies aimed at either epidemiological assessment or elucidation of molecular pathways, the considered study attempted to combine these two approaches. According to the available information, vitamin D can influence tumor biology through several possible mechanisms such as regulation of the cell cycle, inhibition of epithelial-to-mesenchymal transition, regulation of the tumor microenvironment, and modulation of inflammation. Nevertheless, although the proposed use of vitamin D in cancer therapy appears biologically plausible based on current mechanistic evidence, it remains unjustified at this stage due to insufficient clinical support for its efficacy. Clinicians should acknowledge that while the underlying biological rationale is compelling, existing evidence does not currently substantiate the use of vitamin D as a therapeutic intervention for cancer.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497362"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Molecular Hydrogen in Biomedicine: A Comprehensive Review of Mechanisms, Multi-system Therapeutic Effects, and Emerging Delivery Strategies.","authors":"Qiaoyu Zhang, Jingyu Liu, Yawei Zhang, Zijie An, Lianzong Hang, Chen Gu, Yue Mao, Jia Zhu, Rui Zhao, Yongqiang Zhang, Kun Zhu","doi":"10.1177/10815589261497358","DOIUrl":"https://doi.org/10.1177/10815589261497358","url":null,"abstract":"<p><p>Molecular hydrogen (H₂) has attracted increasing interest as a potential therapeutic agent because of its redox-modulating and anti-inflammatory properties. This review summarizes current evidence regarding its biological mechanisms, multisystem effects, and emerging delivery strategies. Experimental studies suggest that H₂ may attenuate oxidative injury and inflammatory signaling through both direct interactions with highly reactive species and indirect modulation of pathways involving Nrf2, NF-κB, NLRP3, mitochondrial function, and immune regulation. Protective effects have been reported across cardiovascular, neurological, respiratory, digestive, renal, musculoskeletal, and metabolic disease models. However, the available evidence remains predominantly preclinical, whereas human studies are comparatively limited and heterogeneous. The optimal route of administration, dose, treatment duration, pharmacokinetic profile, and long-term safety and efficacy also remain insufficiently defined. Emerging delivery platforms may improve local retention and controlled release but remain largely experimental. Overall, molecular hydrogen represents a promising adjunctive therapeutic strategy, although further mechanistic validation and well-designed clinical studies are required before routine clinical application.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497358"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Immune Effector Cell-Associated Neurotoxicity Syndrome in Hematological Malignancy Patients Treated with CAR-T Cell: A Systematic Review.","authors":"Kareem Latif, Jasmine Cha, Robert Niihara, Jerry Qi, Mohammad Dastjerdi, Mojtaba Akhtari","doi":"10.1177/10815589261497365","DOIUrl":"https://doi.org/10.1177/10815589261497365","url":null,"abstract":"<p><strong>Background: </strong>Immune effector cell-associated neurotoxicity syndrome (ICANS) is a clinically significant complication of chimeric antigen receptor T-cell (CAR-T) therapy, with reported incidence varying across products and indications. However, the overall and product-specific risks of ICANS have not been comprehensively quantified. The aim of this study was to determine the pooled incidence of any-grade and severe (grade ≥3) ICANS across FDA-approved CAR-T products used in hematologic malignancies.</p><p><strong>Methods: </strong>We performed a meta-analysis of prospective and retrospective studies evaluating six FDA-approved CAR-T products (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel). The primary endpoint was incidence of any-grade ICANS; the secondary endpoint was incidence of grade ≥3 ICANS. Pooled incidence proportions were calculated using random-effects models. Heterogeneity was assessed using Cochran's Q and I² statistics.</p><p><strong>Results: </strong>Sixty analytic cohorts including 8,411 patients were analyzed. The pooled random-effects incidence of any-grade ICANS was 29.7% (95% CI, 24.3%-35.5%), and grade ≥3 ICANS occurred in 9.9% (95% CI, 7.4%-12.8%). Heterogeneity remained substantial for any-grade ICANS (Q=1822.40; I²=96.76%; τ²=0.22) and grade ≥3 ICANS (Q=965.44; I²=93.89%; τ²=0.11).Incidence varied markedly by product, with highest rates observed in CD28-based CD19 CAR-T therapies (axicabtagene ciloleucel and brexucabtagene autoleucel) and lower rates in 4-1BB-based CD19 and BCMA-targeted therapies.</p><p><strong>Conclusions: </strong>Approximately one in four CAR-T recipients develop ICANS, with nearly one in ten experiencing severe neurotoxicity. Risk varies significantly by product, supporting the need for product-specific risk stratification, monitoring strategies, and toxicity mitigation approaches.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497365"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Association of Systemic Immune-inflammation Index and Systemic Inflammation Response Index with All-cause Mortality in the Critically Ill Population with Coronary Heart Disease and Heart Failure - A Study Based on the MIMIC-IV Database.","authors":"Siyuan Zhou, Lianlian Liu, Jia Han, Fengfeng Lv, Lei Zhao, Rongcheng Zhao, Zesheng Xu","doi":"10.1177/10815589261497360","DOIUrl":"https://doi.org/10.1177/10815589261497360","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the associations of the systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) with all-cause mortality (ACM) in critically ill patients with coronary heart disease (CHD) and heart failure (HF).</p><p><strong>Methods: </strong>Data from critically ill patients with CHD and HF were extracted from the MIMIC-IV database. Cox proportional hazards models were used to examine the associations of SII and SIRI with ACM. Restricted cubic spline (RCS) models were applied to assess potential nonlinear relationships between SII, SIRI, and ACM. The area under the receiver operating characteristic (ROC) curve (AUC), integrated discrimination improvement (IDI), and net reclassification improvement (NRI) were calculated to evaluate the incremental predictive value of adding SII and SIRI to the Sequential Organ Failure Assessment (SOFA) score.</p><p><strong>Results: </strong>A total of 1,865 participants were included. Cox proportional hazards models showed that patients in the third quartile (Q3) and fourth quartile (Q4) of SII had significantly higher risks of 30-day ACM. RCS analyses demonstrated nonlinear associations between SII, SIRI, and ACM. The ROC analysis showed that the AUCs of SII and SIRI were 0.651 and 0.685, respectively, indicating moderate discriminatory ability for adverse outcomes. In addition, incorporating SII and SIRI into the SOFA score improved the predictive accuracy of the model.</p><p><strong>Conclusions: </strong>SII and SIRI were associated with adverse prognosis in critically ill patients with CHD complicated by HF and may have potential prognostic value.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497360"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Transcutaneous Electrical Acupoint Stimulation for Postoperative Gastrointestinal Recovery: A Systematic Review and Meta-Analysis Using a Composite Stimulation-Pattern Framework.","authors":"Bo Zhang, Xiaodie Deng, Xiu Yang, Jiande D Z Chen","doi":"10.1177/10815589261497363","DOIUrl":"https://doi.org/10.1177/10815589261497363","url":null,"abstract":"<p><strong>Background & aims: </strong>Transcutaneous electrical acupoint stimulation (TEAS) promotes postoperative gastrointestinal recovery. However, existing protocols lack standardization due to unaddressed methodological collinearity between frequency and waveform in previous analyses. We aimed to evaluate the efficacy of TEAS following abdominal surgery and examine whether treatment effects varied across stimulation parameters.</p><p><strong>Methods: </strong>We searched four major databases from inception to April 2026 for randomized controlled trials (RCTs) comparing TEAS with sham/standard care. Frequency and waveform were systematically reconstructed into a composite \"Stimulation Pattern\" (Intermittent/Fixed vs. Dilatational/Alternating). Data were pooled using a random-effects model.</p><p><strong>Results: </strong>Twenty RCTs comprising 2,615 patients were included. TEAS significantly accelerated the time to first flatus (MD = -9.08 h, P < 0.0001) and first defecation (MD = -16.48 h, P < 0.0001), and reduced the incidence of strictly defined POI (3 trials; RR = 0.78, 95% CI 0.64-0.96; P = 0.0214). TEAS also shortened hospital stay and mitigated postoperative nausea, vomiting, and pain. The intermittent/fixed stimulation pattern was associated with a greater reduction in time to first flatus than the dilatational/alternating pattern (interaction P = 0.0008). Adverse events were minimal (0%-1.8%).</p><p><strong>Conclusions: </strong>TEAS safely accelerates gastrointestinal motility recovery. While an optimal protocol remains to be established, the intermittent/fixed stimulation pattern appears to be a promising candidate configuration. Longer or more frequent treatment did not show clear additional benefit, supporting evaluation of a 30-min once-daily regimen as a pragmatic, resource-efficient strategy in future prospective trials.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497363"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESS: Relation Between Thyroid Hormones Levels and Diabetic Peripheral Neuropathy in Diabetic Patients without Clinical Thyroid Dysfunction A Systematic Review and Meta-analysis.","authors":"Mohamed A Younes, Ahmed Mahmoud Abdullah Salem, Hamada Hamdy Hassan Abdellatif, Ahmed Mohammed Mostafa Ibrahim, Mohammed Aboud Omar Abo Zied, Mohamed Gamil Said Elgohary, Ayman Nooreldeen Mostafa Abdellateef, Ahmed Abdelaziz Elsayed Atiia Elhagary, Hany Gamal Abozaid Metwaly, Hamdy Saeed Ahmed Othman, Abdelrahman Noureldeen Abdelal, Ayman Sayed Ahmed Mohamed Ayad, Kawashty Ragab Mohamed","doi":"10.1177/10815589261497357","DOIUrl":"https://doi.org/10.1177/10815589261497357","url":null,"abstract":"<p><p>The relation between diabetes and thyroid dysfunction is multidimensional. The present study aimed to critically revise the published literature on the relation between thyroid hormone levels and diabetic peripheral neuropathy (DPN) in Type II diabetes (T2DM) patients without clinical thyroid dysfunction. The present systematic review was performed in line with recommendations of the Preferred Reporting Items for Systematic review and Meta Analyses (PRISMA) guidelines. The review was conducted on 10 studies including 7559 patients. They comprised 2892 patients (38.3 %) with DPN and 4667 patients (61.7 %) without DPN. Pooled analysis revealed significantly lower FT3 levels in patients with DPN as compared to patients without DPN [SMD (95% CI): -1.03 (-1.80, -0.25), p=0.009]. Also, it was shown that patients with DPN had significantly lower FT4 levels when compared with patients without DPN [SMD (95% CI): -0.27 (-0.50, -0.05), p=0.02]. However, no significant differences were found between the studied subgroups regarding pooled TSH levels [SMD (95% CI): 0.21 (-0.08, 0.55), p=0.15]. Conclusively, in T2DM patients without clinical thyroid dysfunction, patients with DPN had significantly lower FT3 and FT4 levels while TSH levels were comparable between patients with DPN and patients without.</p>","PeriodicalId":520677,"journal":{"name":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","volume":" ","pages":"10815589261497357"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}